Abstracts tagged "Disease Activity"

Abstract Number: 1912 • ACR Convergence 2024
Greater Glucocorticoid and Less Biologic/Targeted Therapy Use in Midwest PsA Patients Despite Prevalent Comorbidity
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Cassie Clinton⁵, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: There is regional variation in the clinical characteristics, treatment, and outcomes of patients with inflammatory arthritis in the US. Despite a higher reported prevalence of…
Abstract Number: 2252 • ACR Convergence 2024
Long-term Efficacy of Filgotinib Monotherapy and Combination Therapy: Interim Results from a Post Hoc Analysis of the FINCH 4 Study
Maya H. Buch¹, Patrick Verschueren², Roberto Caporali³, Thomas Huizinga⁴, Edmund V. Ekoka Omoruyi⁵, Dick de Vries⁶, Jeffrey Ritsema⁷, Francesco De Leonardis⁸ and Daniel Aletaha⁹, ¹Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom, ²Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Department of Rheumatology, Leiden University, Leiden, Netherlands, ⁵Biostatistics, Galapagos NV, Mechelen, Belgium, ⁶Clinical Development, Galapagos BV, Leiden, Netherlands, ⁷Medical Affairs, Galapagos BV, Leiden, Netherlands, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria
Background/Purpose: Filgotinib (FIL) is a preferential Janus kinase 1 inhibitor for the treatment of moderate to severe RA. FINCH 4 (NCT03025308) is an ongoing, open-label,…
Abstract Number: 2415 • ACR Convergence 2024
Characterizing the Population with Suspected Lupus Nephritis in Care of a Community Rheumatology Network
Nehad Soloman¹, Jawad Bilal², Romy Cabacungan³, Scott Milligan⁴, Andrew Sharobeem⁵, John Tesser⁶ and Henry Leher⁷, ¹Arizona Arthritis & Rheumatology Associates, P.C., Glendale, AZ, ²University of Arizona, Tucson, AZ, ³Arizona Arthritis & Rheumatology Associates, P.C., Tucson, AZ, ⁴Trio Health, Louisville, CO, ⁵AARA, Peoria, AZ, ⁶Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ⁷Aurinia Pharma, Stowe, VT
Background/Purpose: Lupus nephritis (LN) has been estimated to develop in up to 40% of all patients with systemic lupus erythematosus (SLE), with higher rates in…
Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Dansoa Tabi-Amponsah¹, Lisa Stamp², Anne Horne³, Jill Drake⁴, Sarah Stewart⁵, Gregory Gamble³, Keith Petrie¹ and Nicola Dalbeth³, ¹The University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Auckland University of Technology, Auckland, New Zealand
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
Abstract Number: 0545 • ACR Convergence 2024
Missing Data in Observational Studies: Investigating Cross-sectional Single Imputation Methods for Assessing Disease Activity in Axial Spondyloarthritis
Stylianos Georgiadis¹, Marion Pons², Simon Horskjær Rasmussen², Merete Hetland³, Louise Linde², Daniela DiGuiseppe⁴, Brigitte Michelsen⁵, Johan Karlsson Wallman⁶, Tor Olofsson⁷, Karel Pavelka⁸, Jakub Závada⁸, Bente Glintborg⁹, Anne Gitte Loft¹⁰, Catalin Codreanu¹¹, Daniel Melim¹², Diogo Esperança Almeida¹³, Tore K. Kvien¹⁴, Vappu Rantalaiho¹⁵, Ritva Peltomaa¹⁶, Bjorn Gudbjornsson¹⁷, Olafur Palsson¹⁸, Ovidiu Rotariu¹⁹, Ross MacDonald¹⁹, Ziga Rotar²⁰, Katja Perdan-Pikmajer²⁰, Karin Laas²¹, Florenzo Iannone²², Adrian Ciurea²³, Mikkel Ostergaard²⁴ and Lykke Oernbjerg¹, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Glostrup, Denmark, ³Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ⁴Karolinska Institutet, Stockholm, ⁵Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ⁶Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Skane Lan, Sweden, ⁷Lund University, Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund, Sweden, Lund, Sweden, ⁸Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁹DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ¹⁰Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹¹University of Medicine and Pharmacy, Bucharest, Romania, ¹²Hospital Egas Moniz, Lisbon, Portugal, ¹³Hospital de Braga, Braga, Portugal, ¹⁴Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁵Tampere University Hospital, Tampere University and Kanta-Häme Central Hospital, Tampere, Finland, ¹⁶Helsinki University Hospital and University of Helsinki, Helsinki, Finland, ¹⁷Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁸University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁹University of Aberdeen, Aberdeen, United Kingdom, ²⁰University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ²¹East-Tallinn Central Hospital, Tallinn, Estonia, ²²Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ²³University Hospital Zurich, Zürich, Switzerland, ²⁴Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: In observational studies, several longitudinal methods have been proposed to impute missing data of an individual by using the available information of the same…
Abstract Number: 0626 • ACR Convergence 2024
Impact of the Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) in Systemic Lupus Erythematosus Patients from the Almenara Lupus Cohort
Manuel Ugarte-Gil¹, RV, Gamboa-Cardenas², Victor Pimentel-Quiroz³, Cristina Reategui⁴, Claudia Elera Fitzcarrald⁵, Samira García-Hirsh⁶, José Alfaro-Lozano⁶, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela Alarcon⁷, ¹Universidad Cientifica del Sur, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Lima, Peru, ³Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ⁴Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen/Universidad San Ignacio de Loyola, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Physician-reported disease activity has a modest association with patient-reported outcomes (PROs) in systemic lupus erythematosus patients. The aim of this study is to evaluate…
Abstract Number: 0867 • ACR Convergence 2024
Development of a Remote Patient Monitoring System Based on a Novel Digital Biomarker for Swelling in Rheumatoid Arthritis
Marc Blanchard¹, Cinja Koller², Jules Maglione³, Patrick Hermann¹ and Thomas Hügle³, ¹Lausanne University Hospital, Lausanne, Vaud, Switzerland, ²Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) care faces challenges due to a shortage of healthcare providers, an increasing patient population and the remote locations of many patients.…
Abstract Number: 1331 • ACR Convergence 2024
Does Refractory Rheumatoid Arthritis Status Matter in Modeling Patient Global Assessment Trajectories over 20 Years in a Large US Registry?
Sofia Pedro¹, Kristin Wipfler², Urbano Sbarigia³, Federico Zazzetti⁴, Anna Sheahan⁵, Patti Katz⁶ and Kaleb Michaud⁷, ¹Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³Johnson & Johnson Innovative Medicine, Brussels, Belgium, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Janssen, Chapel Hill, NC, ⁶UCSF, San Rafael, CA, ⁷University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Refractory rheumatoid arthritis (reRA) is characterized by an inadequate response to multiple DMARDs. Many factors including environment, comorbidities, sociodemographics, and the treatment itself influence poor…
Abstract Number: 1378 • ACR Convergence 2024
Tocilizumab Effect on the Three Pathways of the Complement System in Patients with Rheumatoid Arthritis
Marta Hernández-Díaz¹, Iván Ferraz-Amaro², Sergio Santos-Concepción³, Javier Castro³, Vanesa Hernandez⁴, Beatriz Tejera Segura⁵, Cristina Luna⁶, Esmeralda Delgado-Frías² and Federico Diaz-González², ¹Hospital Universitario de Canarias, SANTA CRUZ DE TENERIFE, Spain, ²Hospital Universitario de Canarias, La Laguna, Spain, ³Universidad de La Laguna, La Laguna, Spain, ⁴Rheumatology department. Hospital Universitario de Canarias, La Laguna, Spain, ⁵Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las palmas, Spain, ⁶Hospital Universitario Nuestra Señora de La Candelaria, Santa Cruz, Spain
Background/Purpose: Tocilizumab (TCZ) is used in diseases characterized by markedly elevated inflammatory markers and elevated pro-inflammatory cytokines like rheumatoid arthritis (RA), juvenile idiopathic arthritis and…
Abstract Number: 1596 • ACR Convergence 2024
Efficacy of Eosinophil-Targeting Therapies According to Disease Severity in Patients with Eosinophilic Granulomatosis with Polyangiitis
Bernhard Hellmich¹, Peter Merkel², David Jayne³, Benjamin Terrier⁴, Florence Roufosse⁵, Parameswaran Nair⁶, Nader Khalidi⁶, David J. Jackson⁷, Shunsuke Furuta⁸, Lena Börjesson Sjö⁹, Sofia Necander⁹, Anat Shavit¹⁰, Claire Walton¹¹ and Michael Wechsler¹², ¹Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ²University of Pennsylvania, Philadelphia, PA, ³University of Cambridge, Cambridge, United Kingdom, ⁴Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France, ⁵Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁶McMaster University and St Joseph’s Healthcare, Hamilton, ON, Canada, ⁷Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Trust; School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom, ⁸Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹¹Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹²National Jewish Health, Denver, CO
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by asthma, eosinophilia, and small-to-medium size vessel vasculitis, with individual manifestations widely ranging…
Abstract Number: 1942 • ACR Convergence 2024
Electronic Health Literacy and Its Association with Disease Activity in RMD Patients – a Cross Sectional Study
Nasim Nakhost Lotfi¹, Helga Lechner-Radner², Daniela Sieghart¹ and Paul Studenic¹, ¹Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria, Vienna, Austria, ²Medical University Vienna, Department of Internal Medicine III, Division of Rheumatology, Vienna, Austria
Background/Purpose: In the evolving landscape of healthcare, the reliance on digital tools for patient education and management is growing. The effectiveness of these digital resources…
Abstract Number: 2256 • ACR Convergence 2024
Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months
Jia Yi Hee¹, Hendrik Nel², Yann Abraham³, Katrina Chakradeo⁴, Michelle Roch⁴, Tom Lynch⁵, Lyn March⁵, Mihir Wechalekar⁶, Helen Keen⁷ and Ranjeny Thomas⁸, ¹The University of Queensland, Woolloongabba, Queensland, Australia, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Janssen Research and Development, Beerse, Belgium, ⁴The University of Queensland, Brisbane, Australia, ⁵The University of Sydney, Sydney, New South Wales, Australia, ⁶Flinders Medical Centre, Adelaide, Australia, ⁷Fiona Stanley Hospital, Murdoch, Western Australia, Australia, ⁸University of Queensland, Brisbane, Australia
Background/Purpose: More than 50% of people with new-onset RA may achieve remission within the first year on conventional synthetic (cs)-DMARDs. Sustained remission confers better long-term…
Abstract Number: 2419 • ACR Convergence 2024
Clinical and Patient-reported Outcomes in Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS) US Data
Richard Furie¹, Mawuena Binka², Gelareh Atefi³, Stephanie Y. Chen⁴ and Bo Ding⁵, ¹Northwell Health, Manhasset, NY, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ³AstraZeneca, Media, PA, ⁴BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden
Background/Purpose: SLE is an autoimmune disease with diverse manifestations and progression patterns that, via disease activity and effects of standard therapy, imposes a significant burden…
Abstract Number: 0295 • ACR Convergence 2024
Mycophenolate Mofetil in the Treatment of Patients with Isolated Cardiac Sarcoidosis
Namitha Nair¹, Leen Al Saleh², Haya Haddad³, Maria Jaimes Reyes⁴, Vishakha Chetram⁵, Farooq Sheikh⁶, FLORINA CONSTANTINESCU⁷ and Anjani Pillarisetty⁸, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Watson Clinic, Lakeland, FL, ³Medstar Washington Hospital Center, Silver Spring, MD, ⁴Medstar Washington Hospital Center/Georgetown University, Washington, DC, ⁵Inova Schar Heart and Vascular, Falls Chirch, VA, ⁶MedStar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, ⁷MedStar Washington Hospital Center, Washington, DC, ⁸Carson Tahoe Medical Group, Reno, NV
Background/Purpose: Cardiac involvement is seen in approximately a fourth of patients with sarcoidosis, a non-necrotizing granulomatous systemic disease. Among these patients, 25% may have isolated cardiac…
Abstract Number: 0548 • ACR Convergence 2024
Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
David Kiefer¹, Juergen Braun², Uta Kiltz³, Niklas Kolle¹, Lucia Schneider¹, Ioana Andreica⁴, Bjoern Buehring⁵, Philipp Sewerin⁶, Imke Redeker⁷, Styliani Tsiami⁸, Susanne Herbold⁹ and Xenofon Baraliakos⁸, ¹Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁵Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, ⁶Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Ruhr Universität Bochum, Bochum, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Herne, Germany
Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…

« Previous Page
1
…
4
5
6
7
8
…
102
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.